Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 28.68% is 42% above its 5-year average of 20.15%, near the high end of its 5-year range (6.89%–28.68%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.08% above its 12-month average of 26.79%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-06-30): 28.68%.
RETURN ON EQUITY (ROE)
28.68%
RETURN ON EQUITY (ROE) AVG TTM
26.79%
RETURN ON EQUITY (ROE) AVG 3Y
21.41%
RETURN ON EQUITY (ROE) AVG 5Y
20.15%
RETURN ON EQUITY (ROE) AVG 10Y
21.61%
RETURN ON EQUITY (ROE) AVG 15Y
13.78%
RETURN ON EQUITY (ROE) AVG 20Y
7.65%
CURRENT VS TTM AVG
+7.08%
CURRENT VS 3Y AVG
+33.97%
CURRENT VS 5Y AVG
+42.37%
CURRENT VS 10Y AVG
+32.72%
CURRENT VS 15Y AVG
+108.07%
CURRENT VS 20Y AVG
+275.13%
SECTOR MEDIAN · HEALTHCARE
-41.56%
median of 737 covered companies
CURRENT VS SECTOR MEDIAN
+169.01%
vs the sector median at left
Pro-Dex, Inc.
Market Cap
$208.71M
Return on Equity (ROE)
28.68%
TTM Avg
26.79%
3Y Avg
21.41%
5Y Avg
20.15%
Market Cap
$206.82M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.37M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$206.05M
Return on Equity (ROE)
N/A
TTM Avg
-280.12%
3Y Avg
-179.90%
5Y Avg
-133.80%
Market Cap
$211.33M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$206.19M
Return on Equity (ROE)
-36.64%
TTM Avg
6.57%
3Y Avg
27.96%
5Y Avg
27.96%
Market Cap
$211.79M
Return on Equity (ROE)
-45.23%
TTM Avg
-120.85%
3Y Avg
-88.04%
5Y Avg
-69.68%
Market Cap
$203.92M
Return on Equity (ROE)
N/A
TTM Avg
620.74%
3Y Avg
332.27%
5Y Avg
266.26%
Market Cap
$214.41M
Return on Equity (ROE)
-106.27%
TTM Avg
-100.08%
3Y Avg
-64.49%
5Y Avg
-52.22%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pro-Dex, Inc. (PDEX) | $208.71M | 28.68% | 26.79% | 21.41% | 20.15% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.37M | -71.02% | -15.82% | -19.73% | -5.35% |
| Alector, Inc. (ALEC)vs › | $206.05M | N/A | -280.12% | -179.90% | -133.80% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 39.66% | 4.24% | -15.88% | -20.06% |
| Sionna Therapeutics, Inc. (SION)vs › | $206.19M | -36.64% | 6.57% | 27.96% | 27.96% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | -45.23% | -120.85% | -88.04% | -69.68% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $203.92M | N/A | 620.74% | 332.27% | 266.26% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.41M | -106.27% | -100.08% | -64.49% | -52.22% |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 19.38% | 20.63% | -8.44% | -40.10% |
ROE
28.7%
ROA
18.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 28.68% |
| 2026-03-31 | 26.55% |
| 2025-12-31 | 27.23% |
| 2025-09-30 | 26.96% |
| 2025-06-30 | 24.51% |
| 2025-03-31 | 26.55% |
| 2024-12-31 | 21.21% |
| 2024-09-30 | 16.87% |
| 2024-06-30 | 6.89% |
| 2024-03-31 | 14.05% |
| 2023-12-31 | 16.70% |
| 2023-09-30 | 18.23% |
| 2023-06-30 | 23.90% |
| 2023-03-31 | 19.26% |
| 2022-12-31 | 15.62% |
| 2022-09-30 | 15.84% |
| 2022-06-30 | 15.16% |
| 2022-03-31 | 14.84% |
| 2021-12-31 | 21.98% |
| 2021-09-30 | 19.87% |
| 2021-06-30 | 22.16% |
| 2021-03-31 | 30.10% |
| 2020-12-31 | 24.55% |
| 2020-09-30 | 31.29% |
| 2020-06-30 | 32.06% |
| 2020-03-31 | 25.96% |
| 2019-12-31 | 22.23% |
| 2019-09-30 | 22.37% |
| 2019-06-30 | 24.39% |
| 2019-03-31 | 19.42% |
| 2018-12-31 | 18.70% |
| 2018-09-30 | 13.21% |
| 2018-06-30 | 9.38% |
| 2018-03-31 | 12.44% |
| 2017-12-31 | 15.39% |
| 2017-09-30 | 33.34% |
| 2017-06-30 | 37.08% |
| 2017-03-31 | 35.16% |
| 2016-12-31 | 33.09% |
| 2016-09-30 | 13.52% |
| 2016-06-30 | 9.27% |
| 2016-03-31 | 7.74% |
| 2015-12-31 | 3.00% |
| 2015-09-30 | -3.83% |
| 2015-06-30 | -4.31% |
| 2015-03-31 | -4.93% |
| 2014-12-31 | -8.14% |
| 2014-09-30 | -9.59% |
| 2014-06-30 | -5.28% |
| 2014-03-31 | -15.42% |
| 2013-12-31 | -19.20% |
| 2013-09-30 | -18.91% |
| 2013-06-30 | -22.48% |
| 2013-03-31 | -19.26% |
| 2012-12-31 | -15.01% |
| 2012-09-30 | -14.01% |
| 2012-06-30 | -9.18% |
| 2012-03-31 | 6.91% |
| 2011-12-31 | 19.50% |
| 2011-09-30 | 25.44% |
| 2011-06-30 | 25.56% |
| 2011-03-31 | -24.72% |
| 2010-12-31 | -35.59% |
| 2010-09-30 | -35.28% |
| 2010-06-30 | -38.98% |
| 2010-03-31 | 9.89% |
| 2009-12-31 | -18.08% |
| 2009-09-30 | -23.79% |
| 2009-06-30 | -27.15% |
| 2009-03-31 | -33.73% |
| 2008-12-31 | -2.64% |
| 2008-09-30 | -0.96% |
| 2008-06-30 | 2.39% |
| 2008-03-31 | 6.71% |
| 2007-12-31 | 7.65% |
| 2007-09-30 | 4.50% |
| 2007-06-30 | 3.95% |
| 2007-03-31 | 4.37% |
| 2006-12-31 | 2.78% |
| 2006-09-30 | 6.53% |
| 2006-06-30 | 6.84% |
| 2006-03-31 | 12.86% |
| 2005-12-31 | 15.17% |
| 2005-09-30 | 14.48% |
| 2005-06-30 | 16.63% |
| 2005-03-31 | 13.59% |
| 2004-12-31 | 13.92% |
| 2004-09-30 | 15.10% |
| 2004-06-30 | 12.94% |
| 2004-03-31 | 9.69% |
| 2003-12-31 | 7.47% |
| 2003-09-30 | 4.33% |
| 2003-06-30 | 1.79% |
